Literature DB >> 7513334

Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.

R M Cole1, F Robinson, L Harvey, K Trethowan, V Murdoch.   

Abstract

Chemically induced nausea and vomiting is a common symptom of advanced cancer effected through stimulation of dopamine (D2) or serotonin (5-HT3) receptors located in the chemoreceptor trigger zone (CTZ). These may be blocked by therapeutic doses of haloperidol and ondansetron, respectively. This case, reporting on a single patient acting as her own control, establishes that combined blockade of these receptors is sometimes required to relieve intractable nausea and vomiting. It also demonstrates the value of clinical review, audit of care, and quality assurance in the palliative care setting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513334     DOI: 10.1016/0885-3924(94)90147-3

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  7 in total

1.  Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis.

Authors:  Brad E Schwartz; Karen Keller Baker; Andrew J Bleinberger; Amina Lleshi; Raul Cruz-Cano
Journal:  World J Emerg Med       Date:  2021

2.  Clinical management of dying patients.

Authors:  J Gavrin; C R Chapman
Journal:  West J Med       Date:  1995-09

Review 3.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 4.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

5.  Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: a double blind controlled trial.

Authors:  U Ergene; M Pekdemir; E Canda; Z Kirkali; J Fowler; F Coşkun
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

6.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

7.  Stability and compatibility of ondansetron with haloperidol in parenteral admixtures.

Authors:  Gabriel Estan-Cerezo; Carmen Matoses-Chirivella; Leticia Soriano-Irigaray; Ana Cristina Murcia-López; Francisco José Rodríguez-Lucena; Andrés Navarro-Ruiz
Journal:  Eur J Hosp Pharm       Date:  2017-04-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.